INTEGRA Biosciences Partners with HilleVax to Accelerate Norovirus Vaccine Development

INTEGRA Biosciences recently announced its collaboration with HilleVax to expedite the development of a novel norovirus vaccine candidate. As part of the partnership, INTEGRA awarded HilleVax with 50 EVOLVE manual pipettes, GRIPTIPS® pipette tips, and various lab accessories, collectively valued at US $1000. This support will aid HilleVax in advancing its pioneering research aimed at addressing health inequalities and improving patient care globally.

INTEGRA Biosciences has teamed up with HilleVax, a company dedicated to developing innovative vaccines to combat health disparities worldwide. Through their collaboration, INTEGRA has provided HilleVax with essential laboratory equipment and supplies to facilitate the development of a promising norovirus vaccine candidate.

HilleVax, a collaboration between Frazier Healthcare and Takeda, is focused on advancing HIL-214, a virus-like particle vaccine for norovirus currently undergoing Phase II clinical trials. The company’s mission aligns with its founders’ vision of leveraging vaccine technology to bridge healthcare gaps and promote equitable access to treatment.

Dr. Erika Olson, Senior Scientist at HilleVax, expressed enthusiasm for the partnership with INTEGRA, citing the reliability and ergonomic design of their pipettes as instrumental in achieving research goals. The versatility of the EVOLVE pipettes, which can seamlessly adjust between various volume settings, coupled with the secure attachment provided by GRIPTIPS, enhances efficiency and ensures high-quality results.

This collaboration exemplifies the synergy between industry leaders and emerging innovators in the field of biotechnology. By pooling resources and expertise, INTEGRA and HilleVax are poised to make significant strides in vaccine development, ultimately improving healthcare outcomes for individuals worldwide.